Traits: COVID-19;
Trait | Type | #Publications | #Studies | #Associations | Correlations | CpG Island |
---|---|---|---|---|---|---|
COVID-19 | non-cancer disease | 3 | 6 | 482 | Hyper: 64%; Hypo: 22%; NR: 14% | cpg: 6%; shore: 16%; shelf: 11%; other: 67% |
Probe ID | Studies | Correlations | Location | Related genes (transcript: location) | CpG islands | Related traits |
---|---|---|---|---|---|---|
cg13452062 | 2 | Hyper: 0%;Hypo: 0%;NR: 100% | chr1: 79088559 | IFI44L (ENST00000452835: body); IFI44L (ENST00000476521: body); IFI44L (ENST00000370751: body); IFI44L (ENST00000459784: body); IFI44L (ENST00000476876: body); | Other | |
cg04736673 | 2 | Hyper: 0%;Hypo: 0%;NR: 100% | chr10: 61647141 | CCDC6 (ENST00000263102: body); | Other | |
cg17178900 | 2 | Hyper: 0%;Hypo: 0%;NR: 100% | chr1: 205818956 | PM20D1 (ENST00000367136: promoter); PM20D1 (ENST00000460624: promoter); | Island | |
cg17114584 | 2 | Hyper: 0%;Hypo: 100%;NR: 0% | chr11: 613792 | IRF7 (ENST00000525445: body); IRF7 (ENST00000348655: body); IRF7 (ENST00000397566: body); IRF7 (ENST00000397574: body); IRF7 (ENST00000533182: body); IRF7 (ENST00000397570: body); IRF7 (ENST00000528413: promoter); IRF7 (ENST00000469048: body); IRF7 (ENST00000531912: promoter); IRF7 (ENST00000330243: body); IRF7 (ENST00000532326: body); IRF7 (ENST00000525750: promoter); | Shore | |
cg00607627 | 2 | Hyper: 0%;Hypo: 100%;NR: 0% | chr16: 28995994 | RP11-264B17.3 (ENST00000569969: body); LAT (ENST00000395461: promoter); LAT (ENST00000566270: promoter); LAT (ENST00000564277: promoter); LAT (ENST00000562472: promoter); LAT (ENST00000630764: promoter); LAT (ENST00000563964: promoter); LAT (ENST00000354453: promoter); LAT (ENST00000395456: promoter); LAT (ENST00000454369: promoter); LAT (ENST00000360872: promoter); LAT (ENST00000562701: promoter); LAT (ENST00000566177: promoter); LAT (ENST00000568899: promoter); LAT (ENST00000568440: promoter); | Other | |
cg26955963 | 2 | Hyper: 100%;Hypo: 0%;NR: 0% | chr2: 8466005 | LINC00299 (ENST00000430192: promoter); LINC00299 (ENST00000442956: body); LINC00299 (ENST00000444688: body); | Other | |
cg06146977 | 2 | Hyper: 100%;Hypo: 0%;NR: 0% | chr13: 43469464 | EPSTI1 (ENST00000313640: body); EPSTI1 (ENST00000313624: body); EPSTI1 (ENST00000540470: body); EPSTI1 (ENST00000398762: body); EPSTI1 (ENST00000535677: body); | Other | |
cg19285358 | 2 | Hyper: 100%;Hypo: 0%;NR: 0% | chr15: 74928240 | CLK3 (ENST00000561673: body); CLK3 (ENST00000563418: body); EDC3 (ENST00000315127: body); EDC3 (ENST00000565602: body); EDC3 (ENST00000426797: body); EDC3 (ENST00000568176: body); EDC3 (ENST00000569606: promoter); EDC3 (ENST00000562174: body); EDC3 (ENST00000566219: body); | Other | |
cg08689926 | 2 | Hyper: 0%;Hypo: 0%;NR: 100% | chr22: 50322930 | Island | ||
cg26063719 | 2 | Hyper: 0%;Hypo: 0%;NR: 100% | chr10: 17273187 | RP11-124N14.4 (ENST00000605833: promoter); VIM (ENST00000544301: body); VIM (ENST00000224237: body); VIM (ENST00000487938: body); VIM (ENST00000469543: promoter); VIM (ENST00000421459: promoter); VIM (ENST00000637053: promoter); | Shore |
Gene ID | Location | Expression | #Association | Promoter/Body | Correlations | #Related Traits | Most Related traits (#Associations) |
---|---|---|---|---|---|---|---|
RP1-71H24.1; ENSG00000257452 | (-) chr12:113345433-113455556 | 8 | body: 100%; promoter: 0% | Hyper: 75%; Hypo: 25%; NR: 0% | 34 | ||
EPSTI1; ENSG00000133106 | (-) chr13:43460524-43566407 | 7 | body: 71%; promoter: 29% | Hyper: 57%; Hypo: 43%; NR: 0% | 32 | ||
MX1; ENSG00000157601 | (+) chr21:42792231-42831141 | 5 | body: 80%; promoter: 20% | Hyper: 0%; Hypo: 100%; NR: 0% | 34 | ||
AIM2; ENSG00000163568 | (-) chr1:159032274-159116886 | 4 | body: 100%; promoter: 0% | Hyper: 0%; Hypo: 0%; NR: 100% | 37 | ||
OAS2; ENSG00000111335 | (+) chr12:113416200-113449528 | 4 | body: 75%; promoter: 25% | Hyper: 50%; Hypo: 50%; NR: 0% | 27 | ||
OAS1; ENSG00000089127 | (+) chr12:113344582-113371027 | 4 | body: 100%; promoter: 0% | Hyper: 100%; Hypo: 0%; NR: 0% | 17 | ||
RP11-264B17.3; ENSG00000261067 | (+) chr16:28986125-29002096 | 3 | body: 100%; promoter: 0% | Hyper: 0%; Hypo: 100%; NR: 0% | 26 | ||
LIPA; ENSG00000107798 | (-) chr10:90973326-91174314 | 3 | body: 100%; promoter: 0% | Hyper: 0%; Hypo: 100%; NR: 0% | 56 | ||
PM20D1; ENSG00000162877 | (-) chr1:205797150-205819260 | 3 | body: 100%; promoter: 0% | Hyper: 0%; Hypo: 0%; NR: 100% | 16 | ||
IRF7; ENSG00000185507 | (-) chr11:612553-615999 | 3 | body: 100%; promoter: 0% | Hyper: 0%; Hypo: 100%; NR: 0% | 31 |
Study ID | Trait | Ontology | #Associations | #Cohorts | Source | Case | Control |
---|---|---|---|---|---|---|---|
ES01715 | COVID-19 | 40 | 1 | whole blood | Intensive care unit | mild symptomatology | |
ES01716 | COVID-19 | 3 | 1 | whole blood | Intensive care unit | Hospitalization with O2 support | |
ES01717 | COVID-19 | 23 | 1 | whole blood | Hospitalization with O2 support | mild symptomatology | |
ES02125 | COVID-19 | 43 | 1 | whole blood | SARS-CoV-2 RT-PCR severe positive individuals | SARS-CoV-2 RT-PCR negative individuals | |
ES02126 | COVID-19 | 347 | 1 | whole blood | SARS-CoV-2 RT-PCR mild positive individuals | SARS-CoV-2 RT-PCR negative individuals | |
ES02128 | COVID-19 | 26 | 1 | whole blood | COVID‐19 positive patients | COVID‐19 negtive controls |
PMID | Title | Year | Journal | Citation | Datasets |
---|---|---|---|---|---|
33867313 | Epigenome-wide association study of COVID-19 severity with respiratory failure. | 2021 | EBioMedicine | - | GSE168739 |
35933486 | Whole blood DNA methylation analysis reveals respiratory environmental traits involved in COVID-19 severity following SARS-CoV-2 infection. | 2022 | Nat Commun | - | GSE179325 GSE167202 |
34185889 | An epigenome-wide DNA methylation study of patients with COVID-19. | 2021 | Ann Hum Genet | - |